New cerebrospinal fluid biomarkers may improve the diagnosis of cerebral amyloid angiopathy

Wednesday 17 April 2024, 12:30 pm
PhD student
A.M. de Kort MSc.
prof. dr. ir. M.M. Verbeek, prof. dr. C.J.M. Klijn
dr. H.B. Kuiperij, dr. F.H.B.M. Schreuder

Cerebral amyloid angiopathy (CAA) is characterized by accumulation of amyloid-beta protein in the small blood vessels of the brain. This damages the blood vessels and impairs their function. People with CAA have an increased risk of developing a cerebral haemorrhage and cognitive impairment (such as problems with memory, language, attention, concentration, and problem-solving skills). CAA is relatively common: in this thesis it was found that approximately a quarter of all elderly people have CAA. However, CAA only leads to symptoms in a small proportion of those people. Currently, CAA is diagnosed using an MRI scan, but in some cases there may be uncertainty about the diagnosis. In this thesis, several new laboratory tests in cerebral spinal fluid and blood were studied. Some of these so-called “biomarkers” may be able to assist in the diagnosis of CAA and in assessing the effect of experimental treatments for CAA.

Anna de Kort obtained her master's degree in Medicine at Radboud University in 2016 after which she worked as a doctor at the neurology department at the Maasstad hospital in Rotterdam. In 2018, she started her PhD research at the neurology department of the Radboud university medical center.